References

1.       Neu HC. The crisis in antibiotic resistance. Science 1992;257:1064-1073.

2.       Courvalin P. Resistance of enterococci to glycopeptides. Antimicrob Agents Chemother 1990;34:2291-2296.

3.       Neu HC, Davidson S, Briones F. Intravenous/oral ciprofloxacin therapy of infections caused by multiresistant bacteria.  Am J Med 1989;87(Suppl 5A):209-212.

4.       Neu HC and Swarz H. Carbenicillin: clinical and laboratory experience with a parenterally administered penicillin for treatment of Pseudomonas infections. Ann Intern Med  1969;71;903-911.

5.       Parry MF, Neu HC. A comparative study of ticarcillin plus tobramycin versus carbenicillin plus gentamicin for the treatment of serious infections due to gram-negative bacilli. Am J Med 1978;64;961-966.

6.       Pancoast SJ, Jahre JA, Neu HC. Mezlocillin in the therapy of serious infections. Am J Med  1979;67;747-752

7.       Prince AS, Neu HC. Use of piperacillin, a semisynthetic penicillin in the therapy of acute exacerbations of pulmonary disease in patients with cystic fibrosis. J Pediatr 1980;97:148-151.

8.       Scully BE and Neu HC. Clinical efficacy of ceftazidime. Arch Intern Med 1984;144:S7-62

9.       Scully BE, Neu HC. Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa. Am J Med 1985;78:251-261.

10.   Scully BE, Ores C, Prince AS, Neu HC. Treatment of lower respiratory tract infections due to Pseudomonas aeruginosa in patients with cystic fibrosis. Rev Infect Dis 1985;7(Suppl 4):669-674.

11.   Scully BE, Neu HC, Parry MF, Mandell W. Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa. Lancet 1986;1:819-822.

12.   Neu HC. Resistance of Pseudomonas aeruginosa to imipenem. Infect Contr Hosp Epidemiol 1992;13:7-9.

13.   Khardori N, Elting L, Wong F, et al. Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis 1990;12:997-1003.

14.   Neu HC, Aswapokee N, Aswapokee P, Fu KP. HR 756, a new cephalosporin active against gram-positive and gram negative aerobic and anaerobic bacteria. Antimicrob Agents Chemother 1979;15:273-281

15.   Neu HC, Aswapokee N, Fu KP, Aswapokee P. Antibacterial activity of a new I-oxa cephalosporin compared with that of other beta-lactam compounds. Antimicrob Agents Chemother 1979;16:141-149.

16.   Neu HC, Fu KP, Aswapokee N, Aswapokee P, Kung K. Comparative activity with beta-lactamase stability of cefoperazone, a piperazine cephalosporin. Antimicrob Agents Chemother 1979;16:150-157.

17.   Neu HC, Meropol N, Fu KP, Antibacterial activity of ceftriaxone (Rso13-9004), a beta-lactamase stable cephalosporin. Antimicrob Agents Chemother 1981;19:414-423

18.   Neu HC. In vitro activity of ceftazidime, a beta-lactamase stable cephalosporin. J Antimicrob Chemother 1981;8(SupplB): 131-134.

19.   Jacoby GA, Medeiros AA. More extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1991;35:1697-1704.